Pyrotinib in Patients with HER2-Amplified Advanced Non-Small Cell Lung Cancer: A Prospective, Multicenter, Single-Arm Trial.

Zhengbo SongDongqing LvShi-Qing ChenJianjin HuangYuping LiShenpeng YingXiaoyu WuFeng HuaWenxian WangChunwei XuTing BeiChan GaoZhijian SunYiping ZhangShun Lu

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2021)

Pyrotinib provided antitumor efficacy with a manageable safety profile in HER2-amplified NSCLC patients.

Keyphrases

advanced non small cell lung cancer
end stage renal disease
epidermal growth factor receptor
ejection fraction
small cell lung cancer
newly diagnosed
chronic kidney disease
peritoneal dialysis
study protocol
prognostic factors
phase iii
open label
double blind
tyrosine kinase